The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.
Stratakis, C. A.; Tichomirowa, M. A.; Boikos, S.et al.
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes..pdf
[en] The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. The prevalence of germline mutations in MEN1, AIP, PRKAR1A, CDKN1B and CDKN2CI is unknown among pediatric patients with pituitary adenomas (PA). In this study, we screened children with PA for mutations in these genes; somatic GNAS mutations were also studied in a limited number of growth hormone (GH) or prolactin (PRL)-secreting PA. We studied 74 and 6 patients with either isolated Cushing disease (CD) or GH- or PRL-secreting PA, respectively. We also screened four pediatric patients with CD, and four with GH/PRL-secreting tumors who had some syndromic features. There was one AIP mutation (p.Lys103Arg) among 74 CD patients. Two MEN1 mutations that occurred in patients with recurrent or difficult-to-treat disease were found among patients with CD. There was one MEN1 and three AIP mutations (p.Gln307ProfsX104, p.Pro114fsX, p.Lys241X) among pediatric patients with isolated GH- or PRL-secreting PA and one additional MEN1 mutation in a patient with positive family history. There were no mutations in the PRKAR1A, CDKN1B, CDKN2C or GNAS genes. Thus, germline AIP or MEN1 gene mutations are frequent among pediatric patients with GH- or PRL-secreting PA but are significantly rarer in pediatric CD; PRKAR1A mutations are not present in PA outside of Carney complex.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Stratakis, C. A.
Tichomirowa, M. A.
Boikos, S.
Azevedo, M. F.
Lodish, M.
Martari, M.
Verma, S.
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.
Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004: 101: 613-619.
Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008: 8: 563-574.
Daly AF, Rixhon M, Adam C et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006: 91: 4769-4775.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2009 Jul 24. [Epub ahead of print].
Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol 2009: 4: 97-126.
Daly AF, Beckers A. Update on the treatment of pituitary adenomas: familial and genetic considerations. Acta Clin Belg 2008: 63: 418-424.
Scheithauer BW, Laws ER Jr, Kovacs K et al. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987: 4: 205-211.
Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. J Int Med 2009: 266: 5-18.
Asa SL, Somers K, Ezzat S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. J Clin Endocrinol Metab 1998: 83: 3210-3212.
Kaltsas GA, Kola B, Borboli N et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol 2002: 57: 443-448.
Lania AG, Mantovani G, Ferrero S et al. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res 2004: 64: 9193-9198.
Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999: 140: 573-576.
Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006: 103: 15558-15563.
Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006: 312: 1228-1230.
Daly AF, Vanbellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007: 92: 1891-1896.
Cazabat L, Libe R, Perlemoine K et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007: 157: 1-8.
Georgitsi M, Raitila A, Karhu A et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 2007: 104: 4101-4105.
Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/ p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007: 92: 3321-3325.
Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009: 94: 1826-1834.
Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002: 87: 457-465.
Matsuzaki LN, Canto-Costa MH, Hauache OM. Cushing's disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene. Clin Endocrinol 2004: 60: 142-143.
Rix M, Hertel NT, Nielsen FC et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol 2004: 151: 709-715.
Bilodeau S, Vallette-Kasic S, Gauthier Y et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006: 20: 2871-2886.
Karl M, Von Wichert G, Kempter E et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996: 81: 124-129.
Kawashima ST, Usui T, Sano T et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol 2009: 70: 656-657.
Hao W, Skarulis MC, Simonds WF et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 2004: 89: 3776-3784.
Stock JL, Warth MR, Teh BT et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 1997: 82: 486-492.
Drori-Herishanu L, Horvath A, Nesterova M et al. An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein. Horm Metab Res 2009: 41: 630-634.
Mai PL, Korde L, Kramer J et al. A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep 2007: 1: 9.
Nandagopal R, Vortmeyer A, Oldfield EH et al. Cushing's syndrome due to a pituitary corticotropinoma in a child with tuberous sclerosis: an association or a coincidence? Clin Endocrinol 2007: 67: 639-641.
Stratakis CA, Schussheim DH, Freedman SM et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2000: 85: 4776-4780.
Ozawa A, Agarwal SK, Mateo CM et al. The parathyroid/ pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007: 92: 1948-1951.
Sandrini F, Kirschner LS, Bei T et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 2002: 39: e78.
Bossis I, Voutetakis A, Matyakhina L et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004: 41: 596-600.
Dogan RI, Getoor L, Wilbur WJ et al. SplicePort-an interactive splice-site analysis tool. Nucl Acids Res 2007: 35: W285-W291.
Bertherat J, Horvath A, Groussin L et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009: 94: 2085-2091.
Georgitsi M, De Menis E, Cannavo S et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol 2008: 69: 621-627.
Leontiou CA, Gueorguiev M, Van Der Spuy J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008: 93: 2390-2401.
Yu R, Bonert V, Saporta I et al. Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 2006: 91: 5126-5129.
